Black Diamond Therapeutics (BDTX) Liabilities and Shareholders Equity (2018 - 2026)

Black Diamond Therapeutics (BDTX) has reported Liabilities and Shareholders Equity for 9 consecutive years, with $125.0 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Liabilities and Shareholders Equity fell 24.86% year-over-year to $125.0 million; the trailing twelve-month figure through Jun 2026 stood at $558.7 million (down 7.37% YoY), and the FY2025 full-year result was $143.0 million, up 16.61% from the prior year.
• Liabilities and Shareholders Equity fell to $125.0 million in Q2 2026 per BDTX's latest filing, from $132.9 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $219.5 million in Q1 2022 and bottomed at $119.9 million in Q2 2023.
• Historically, Liabilities and Shareholders Equity has averaged $155.3 million across 5 years, with a median of $153.1 million in 2022.
• The sharpest annual moves came in 2023 and 2024: Liabilities and Shareholders Equity tumbled 39.71% in 2023, then climbed 25.11% in 2024.
• Over 5 years, Liabilities and Shareholders Equity stood at $156.3 million in 2022, then rose by 1.48% to $158.6 million in 2023, then fell by 22.66% to $122.6 million in 2024, then gained by 16.61% to $143.0 million in 2025, then fell by 12.57% to $125.0 million in 2026.
• According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $125.0 million, $132.9 million, and $143.0 million for Q2 2026, Q1 2026, and Q4 2025 respectively.